免疫染色
程序性细胞死亡
免疫组织化学
重症肌无力
信使核糖核酸
细胞凋亡
癌症研究
临床意义
生物
医学
病理
癌症
PD-L1
内科学
生物化学
免疫疗法
基因
作者
Rossana Berardi,Gaia Goteri,Alessandro Brunelli,Silvia Pagliaretta,V. Paolucci,Miriam Caramanti,Silvia Rinaldi,Majed Refai,Cecilia Pompili,Francesca Morgese,Mariangela Torniai,Giulia Marcantognini,Giulia Ricci,Paola Mazzanti,Azzurra Onofri,Francesca Bianchi,Armando Sabbatini,Stefano Cascinu
标识
DOI:10.1080/14728222.2020.1790529
摘要
Background The aim of the study was to investigate Programmed cell Death protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) and their mRNA expression in thymic epithelial tumors (TETs).Research design and methods We analyzed 68 samples of formalin-fixed paraffin-embedded tissue (63 thymomas and 5 thymic carcinomas). PD-1 and PD-L1 protein expression were evaluated by immunohistochemistry, and mRNA expression was evaluated by real-time PCR.Results M/F ratio was 33/35, and median age was 60.5 years. Twenty patients had Myasthenia Gravis (MG). In the subgroup with large tumors (>5 cm), PD-L1 mRNA overexpression was significantly associated with worse prognosis vs. patients with no mRNA overexpression (p = 0.0083) and simultaneous PD-L1 immunostaining (>1%); PD-L1 mRNA overexpression was significantly associated with worse prognosis, respect to patient with PD-L1 negative immunostaining, and no PD-L1 mRNA overexpression (p = 0.0178). The elderly patients (>60 years) with large tumors showed worse prognosis (p = 0.0395). PD-L1 immunostaining (>50%) resulted to be significantly associated with MG.Conclusions Our data suggest the potential involvement of the PD-1 and PD-L1 pathway in TETs' progression. According to our results, it may be helpful to design future trials with anti-PD-1 drugs to establish high-risk patients after surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI